A study was carried out on the comparative efficacy of Lopid, Mevacor, Bezalip and Lasona in sixteen hyperlipidemic subjects. All the subjects were on Lopid at least for the last 15 days. Lopid therapy was discontinued after determining blood lipid profile of the subjects on day zero (day of 1st contact). The subjects were divided into three groups and after a washout period of 15 days, they were given three different drugs for the next 15 days. Subjects in group a (6), b (5) and c (5) received Mevacor, Bezalip and lasona respectively. In the present study mevacor was found to be the most potent hypolipidemic drug in lowering blood cholesterol and Low density lipoprotein (LDL) while lopid was most effective in keeping blood Triglycerides (TG) and High density lipoproteins (HDL) level within the desired limits. Bezalip and Lasona were also sufficiently effective in changing blood lipid profile, but lasona showed a negligible effect on HDL rise as compared with Bezalip or any other drug used in this study.

译文

:对Lopid,Mevacor,Bezalip和Lasona在16个高脂血症受试者中的比较疗效进行了研究。至少最近15天,所有受试者均接受Lopid治疗。在第零天(第一次接触的当天)确定受试者的血脂状况后,停止进行大剂量治疗。将受试者分为三组,在15天的冲洗期后,在接下来的15天中给他们三种不同的药物。 A(6),b(5)和c(5)组的受试者分别接受了Mevacor,Bezalip和lasona。在本研究中,发现甲氧萘韦尔是降低血液胆固醇和低密度脂蛋白(LDL)的最有效的降血脂药,而Lopid最有效地将血液甘油三酸酯(TG)和高密度脂蛋白(HDL)的水平保持在所需限度内。 Bezalip和Lasona在改变血脂方面也足够有效,但与Bezalip或本研究中使用的任何其他药物相比,lasona对HDL升高的影响可忽略不计。

+1
+2
100研值 100研值 ¥99课程
检索文献一次
下载文献一次

去下载>

成功解锁2个技能,为你点赞

《SCI写作十大必备语法》
解决你的SCI语法难题!

技能熟练度+1

视频课《玩转文献检索》
让你成为检索达人!

恭喜完成新手挑战

手机微信扫一扫,添加好友领取

免费领《Endnote文献管理工具+教程》

微信扫码, 免费领取

手机登录

获取验证码
登录